LY3016859

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Chronic Low-back PainDiabetic NephropathyDiabetic Peripheral Neuropathic PainOsteoarthritis

Phase 1

Study of LY3016859 in Participants With Diabetic Nephropathy

CompletedNCT01774981

Eli Lilly and CompanyDiabetic Nephropathy

Start: 2013-03-31End: 2015-08-31Updated: 2019-09-19

Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

CompletedNCT04456686

Eli Lilly and CompanyOsteoarthritis

Start: 2020-07-01End: 2021-08-26Updated: 2023-11-14

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain

CompletedNCT04476108

Eli Lilly and CompanyDiabetic Peripheral Neuropathic Pain

Start: 2020-07-15End: 2021-11-11Updated: 2023-11-14

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

CompletedNCT04529096

Eli Lilly and CompanyChronic Low-back Pain

Start: 2020-08-25End: 2021-10-04Updated: 2023-11-30

Related Papers

Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain.

2025-04-23